YORK, March 18, 2023 /PRNewswire/ -- Aquavit
Holdings has submitted to FDA an IND for its DTX-024, for the
treatment of palmar hyperhidrosis using its patented microchannel
technology™. DTX-024 is a highly purified and clinically
tested injectable neuromodulator derived from neurotoxins produced
by Clostridium botulinum.
"The neurotoxin market is expanding
rapidly, with increasing demand for innovative products and
personalized treatment plans." -- Churl-Su
Kwon, CMO Aquavit.
Alongside Aquavit's biosimilar program for its botulinum toxin,
this will be the first in the world, indicated for palmar
hyperhidrosis, approved by FDA.
Aquavit has been investing in proprietary delivery technologies
and related intellectual property for botulinum toxin. This is a
strategic move that puts them ahead of the curve in the
fast-growing multi-billion-dollar botulinum toxin market.
To effectively execute the strategy, Aquavit has recently
bolstered its executive team with seasoned veterans from the
industry and the academia.
Dr. David Crean, PhD, MBA has
been named Chief Financial Officer of Aquavit Holdings. He has buy-
and sell-side expertise in mergers & acquisitions (M&A),
partnering and investments within the life sciences and healthcare
sectors working within strategic biopharmaceutical companies,
private equity, investment banking and venture capital. He
commenced his career within biopharmaceutical companies more than
30 years ago, most notably at Allergan, an Abbvie Company, where he
lead deal execution for both technology, product, and company
acquisitions and divestitures across a broad range of therapeutic
areas and business units including injectable and topical medical
aesthetics, dermatology, neurology, and ophthalmology. He serves on
several boards including both public and private companies and has
been awarded numerous recognitions including San Diego's 500 Most Influential people for
the past four years (2019 -2022), 2020 Top Thought Leaders by
Axial, M&A Advisor of the Year in 2019, and the 2018 Healthcare
Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a
Registered Investment Banking Representative of BA Securities LLC,
Member FINRA SIPC.
Dr. Churlsu Kwon, MD. PhD. MPH., has been named Chief Medical
Officer. He is a trained neurosurgeon and neuroscientist who brings
a wealth of experience and knowledge to scientific developments,
drug development and approval, and new drug discovery. He holds his
degrees from University of Oxford and
Harvard Medical School and currently
holds an academic position at Columbia Medical School.
With Aquavit's proven track record of developing and launching
global brands, such as AQUAGOLD®, the company has
demonstrated their ability to successfully bring innovative
products to market. With their deep knowledge of botulinum toxin
and extensive network of physicians, Aquavit is well-positioned to
make a significant impact in the industry.
"The neurotoxin market is expanding rapidly, with increasing
demand for innovative products and personalized treatment plans.
There is currently no FDA approval for palmar hyperhidrosis and
through our novel route of administration we will be able to offer
new solutions to meet the evolving needs of patients in pathologies
that are extremely debilitating. The provision of access for this
population is a step in the right direction towards improving their
health and well-being. " Churl-Su Kwon, CMO Aquavit.
Aquavit is an innovative healthcare
company that provides a comprehensive range of proprietary
pharmaceutical, biotech and medical device technologies. Aquavit
focuses on personalized medicine to improve patients' health,
maximize the efficiency of our medical community, and support the
pharmacoeconomics of payers.
View original content to download
SOURCE Aquavit Holdings